Eledon Pharmaceuticals Announces Positive Patient-Reported Outcomes from Phase 2 BESTOW Trial

Article summary

Eledon Pharmaceuticals reported new data from its Phase 2 BESTOW trial showing that its investigational therapy, tegoprubart, provides sustained improvements in quality of life and symptom burden compared to tacrolimus in kidney transplant patients.